Novo Nordisk is licensing United Laboratories’ experimental triple agonist obesity drug, UBT251, for $200M upfront, with potential payments up to $1.8B. This move strengthens its pipeline...
Eli Lilly unites healthcare and research to create medicines that improve the lives of people around the world. Harnessing the power of biotechnology, chemistry, and genetics, its scientists are...